Flexible MoS ₂ ‐Embedded Human Serum Albumin Hollow Nanocapsules with Long Circulation Times and High Targeting Ability for Efficient Tumor Ablation

Adv. Funct. Mater. 2018, 1804081 DOI: 10.1002/adfm.201804081 The major organs (heart, liver, spleen, lungs, and kidneys) of mice after intravenous injection of the MoS2/HSA hollow nanocapsules at the dosages of 5, 10, 20 mg kg−1 for 28 days were analyzed using H&E staining. There was no significant acute or chronic pathological injury, inflammation, or necrosis (Figure 2g), indicating that the MoS2/HSA hollow nanocapsules have excellent biocompatibility. The originally published image of the heart in the 10 mg kg−1 dosage group was repeatedly clipped and used again in Figure 2g for the 20 mg kg−1 dosage group in error. As neither of these images show significant differences, the overall conclusions of this figure, as well as the paper, are unaffected. The corrected H&E staining figure of heart of the mice injected with the dosage of 20 mg/kg is shown below. The authors sincerely apologize for any inconvenience caused.